Novavax COVID-19 vaccine

The Novavax COVID-19 vaccine, codenamed NVX-CoV2373, is a COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), that is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C (36 to 46 °F) refrigerated temperatures.

Novavax COVID-19 vaccine

The Novavax COVID-19 vaccine, codenamed NVX-CoV2373, is a COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), that is undergoing trials in India under the brand name Covovax. It requires two doses and is stable at 2 to 8 °C (36 to 46 °F) refrigerated temperatures.